Navigation Links
Cytomegalovirus in Biological Technology

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

... maribavir clinical development program for prophylaxis against cytomegalovirus disease in transplant patients based on the preliminary analysis of phase ... currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, ...

AlphaVax Announces New CMV Advisory Board

... TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has assembled its cytomegalovirus (CMV) Advisory Board to provide expertise and advice as the company moves ... to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV ....

Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer

... with smallpox vaccination, as well as for the treatment of infections that cause morbidity and mortality in immunocompromised patients such as cytomegalovirus (CMV) and BK virus. Chimerix's pipeline includes an anti-HIV drug, CMX157, in late-stage preclinical studies. Chimerix is also advancing programs ...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Present at Two June Healthcare Conferences

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

... program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections. "Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new class ...

Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001

... to loss of the kidney graft, or to uncontrolled bleeding in the bladder. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease, a viral disease that may lead to blindness or severe gastrointestinal disease after bone marrow transplant. CMX001 is being developed ...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

... program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections. "Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new class ...

ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ViroPharma routinely posts ...

ViroPharma to Present at Three October Healthcare Conferences

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD). ...

ViroPharma to Present at Three September Healthcare Conferences

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...

Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers

... viruses and the cells they infect. Enveloped viruses are responsible for about half of all human viral diseases, including HCV, influenza, HIV, cytomegalovirus and hemorrhagic fevers. Scientists believe that bavituximab helps block the ability of viruses to infect cells and also helps stimulate the body's ...

Viropharma Comments On Upcoming FDA Advisory Committee Meeting

... the package insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV) and Clostridium difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com . Certain statements ...

ViroPharma to Present at the Seventh Annual JMP Securities Research Conference

... package insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV) and Clostridium difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ...

Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infections

... viruses and the cells they infect. Enveloped viruses are responsible for about half of all human viral diseases, including HCV, influenza, HIV, cytomegalovirus and other virus strains. Scientists believe that bavituximab helps block the ability of viruses to infect cells and also helps stimulate the body's ...

ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia

... and commercialization of human plasma-derived specialty immunoglobulin preparations for the treatment of several infectious diseases including cytomegalovirus and Enterovirus. Under this agreement, ProMetic would also retain the rights to the hyperimmune products for the North American market. "These ...

ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ...

ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ...

ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ...

ViroPharma Provides 2008 Outlook

... at http://www.viropharma.com/docs/Vancocin_pi_2007.htm ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . Disclosure Notice ...

RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay

... Goodrum FD, Jordan CT, High K & Shenk T. (2002) Human cytomegalovirus gene expression during infection of primary ... applied to amplify RNA from a small number of human cytomegalovirus (HCMV) infected CD34+ progenitor cells to compare the ...

Measurement of Green Fluorescent Protein in the SpectraMax Gemini XS Spectrofluorometer (MaxLine Application Note #44)

... embryonic kidney 293 cells (HEK-293) were transiently transfected with a wild-type GFP expression plasmid (pS65T, Clontech, discontinued product; cytomegalovirus immediate early promoter drives expression of GFP) using Lipofectamine as per manufacturer's instructions (Gibco/Invitrogen, Cat. No. 18324-012). ...

pSilencer 4.1-CMV: Versatile Vectors for Expression of siRNA, miRNA, and mRNA

... experiments in a broad range of cell lines. The vectors carry an RNA polymerase II-type CMV promoter (human cytomegalovirus immediate-early promoter) and an optimized SV40 polyadenylation signal to drive high-level expression of ...

New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways

... domain of any transcription factor fused to the yeast GAL4 DNA binding domain. The pFA-CMV plasmid features a multiple cloning site and the cytomegalovirus (CMV) promoter for convenient construction and high-level expression of fusion trans-activator proteins in a variety of mammalian cell lines. We ...

Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector

... designed for constitutive high-level protein expression in mammalian cells. 3 The vector contains the promoter and enhancer region of the human cytomegalovirus (CMV) ### immediate early gene for constitutive expression of the pDual GC clones in either transiently or stably transfected mammalian cells. ...

Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells

... Transfection Conditions The control plasmid provided with LipoTAXI transfection reagent encodes the beta-galactosidase enzyme controlled by the cytomegalovirus (CMV) promoter. Varying amounts of the reporter plasmid were mixed with different volumes of LipoTAXI transfection reagent and added to cells ...

Mammalian Expression Vector for Efficient Cloning of PCR Fragments

... The pcmv-script PCR cloning kit features the pCMV-Script vector ( figure 1 ), a mammalian expression vector that uses the cytomegalovirus (CMV) promoter for constitutive expression in a wide variety of cell lines. The pCMV-Script vector shares many essential ...

Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance

... plasmid included with LipoTAXI transfection reagent. This plasmid encodes the b -galactosidase enzyme regulated by the cytomegalovirus (CMV) promoter. We used this plasmid DNA (0.5 to 1.5 g) and LipoTAXI reagent (5 to 12.5 l), complexed together in serum-free ...

Improved Vectors for PathDetect Trans-Reporting Systems

... pFA-CREB and pFA-Elk1 plasmids with new, improved fusion trans-activator plasmids. The pFA2-cJun, pFA2-CREB and pFA2-Elk1 plasmids feature the cytomegalovirus (CMV) promoter for expression of fusion proteins in a wide variety of cell lines and the neomycin-resistance gene for facilitating selection of ...

Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts

... After 20 minutes, the cells were transfected with a plasmid expressing the b -galactosidase reporter molecule under the control of the cytomegalovirus promoter (pCMV b GAL). Transfection was performed using either Stratagenes LipoTAXI transfection reagent 3 or a CaPO 4 -mediated ...

Constructing Directional cDNA Libraries from Limited Amounts of RNA

... 6 and features the LIC site. The pCMV-PCR vector shares many attributes of its parental pCMV-Script vector, such as the cytomegalovirus (CMV) promoter ### for constitutive expression in a wide variety of cell lines. It also includes the ...

Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells

... and pEGFP-N3 vectors, which contain sequences encoding the enhanced version of green fluorescent protein (EGFP) whose expression is driven by the cytomegalovirus (CMV) promoter. Convenient restriction sites in these vectors allow fusion of a protein of interest to either the amino- or carboxy-terminus of ...

A New Lambda Vector for Mammalian Expression

... screened, and individual clones can be quickly converted to the pBK-CMV vector for eukaryotic transcription directed by the cytomegalovirus (CMV) immediate early promoter; this results in mid-level expression of cloned genes in mammalian cells. Conclusions Stratagenes ...

An Epitope Tagging Vector for Gene Expression in Mammalian Cells

... to the epitope tag sequences, the pCMV-Tag1 vector contains features for expression of fusion proteins in eukaryotic cells. The cytomegalovirus (CMV) promoter allows constitutive expression of the cloned DNA in a wide variety of mammalian cell lines. The ...
Other Contents
(Date:8/29/2014)... and number of connections in transcription factor networks (TFNs) ... a study published in PLOS Computational Biology ... signature contributes to a network,s resilience against mutations. ... assortativity of TFN models has a greater effect on ... of assortativity," said Dov A. Pechenick, PhD, lead author ...
(Date:8/29/2014)... in German . ... is considered the oldest form of communication. Acting as ... example, the sexual attraction between males and females. Fish ... coordinate reproductive behavior in males and females. Scientists at ... Algarve in Faro, Portugal, and at the Max Planck ...
(Date:8/29/2014)... a cell,s nucleus, chromosomal DNA is tightly bound ... biologists call chromatin. Until about two decades ago, ... mere packing material around which the glamorous DNA ... a greater appreciation for how DNA/histone interactions govern ... research institutions studying the sequence of the genome ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... San Diego, CA (PRWEB) September 01, 2014 ... website daily regarding all the latest information from the ... , The US FDA announced on August 28, ... are recalled (Class I) as the device ... FDA, the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 ... into Heartbeat Experts’ perspectives on stakeholder ... , Download the flash report to speak ... any launching Diabetes product:, , ... an increasingly crowded market ,     Understanding ...
(Date:8/31/2014)... 31, 2014 Just in time for Washington’s ... only wild, sustainable Alaska Salmon, award winning chowder ... Duke's Green Lake location , Sunday, September 28, 2014 ... sample several ethnic salmon BBQ culinary delights. Live music will ... from Hawaii, Puerto Rico and Mexico will be featured. ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
Other TagsOther Tags